2 unknown, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 2 | Unknown 2 |
Follow Mucpharm Pty Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nebulised BromAc in Healthy Volunteers BromAc - COVID-19 Pneumonia, Bromelains Adverse Reaction | Phase 1 | Completed | Mucpharm Pty Ltd | 12 | 2022-07-27 | 2022-09-15 |
| BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Bromelain, Acetylcysteine, Interventional radiology insertion of drain - Pseudomyxoma Peritonei, Peritoneal Cancer | Phase 2 | Unknown | Mucpharm Pty Ltd | 62 | 2022-05-01 | 2022-03-15 |
| Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease Bromelains, Acetylcysteine - COVID-19 Pneumonia, COVID-19 | Phase 1 / Phase 2 | Unknown | Mucpharm Pty Ltd | 30 | 2022-05-01 | 2022-02-28 |
Pneumonia, Ventilator-Associated (2) · Adenocarcinoma, Mucinous (1) · COVID-19 (1) · Medullary cystic kidney disease 1 (1) · Neoplasms, Cystic, Mucinous, and Serous (1) · Pseudomyxoma Peritonei (1)
Acetylcysteine (2) · Bromelains (2) · bromelain and acetylcysteine drug combination (1)
Australia (1)
Alvaro Arjona Sanchez, MD (1) · Armando Sardi, MD (1) · Edward Levine, MD (1) · Frank MP van Haren, MD, PhD (1) · Frank van Haren, MD, PhD (1) · Haroon Choudry, MD (1) · Ignace de Hingh, MD (1)